Citius Pharmaceuticals, Inc. financial data

Symbol
CTXR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
10-Q - Q4 2025 - 13 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 59% % -36%
Quick Ratio 42% %
Debt-to-equity 80% % 107%
Return On Equity -23% % 44%
Return On Assets -20% % 27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20,762,917 shares 169%
Common Stock, Shares, Outstanding 22,376,427 shares 190%
Entity Public Float $11,390,000 USD
Common Stock, Value, Issued $22,376 USD 190%
Weighted Average Number of Shares Outstanding, Basic 21,495,274 shares 187%
Weighted Average Number of Shares Outstanding, Diluted 21,495,274 shares 187%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $3,944,111 USD
Cost of Revenue $789,208 USD
Research and Development Expense $8,629,155 USD -79%
General and Administrative Expense $18,865,818 USD -5.6%
Operating Income (Loss) $37,505,202 USD 12%
Nonoperating Income (Expense) $290,750 USD -110%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $37,795,952 USD 5%
Income Tax Expense (Benefit) $144,000 USD 0%
Net Income (Loss) Attributable to Parent $11,511,505 USD -35%
Earnings Per Share, Basic -2.46 USD/shares 58%
Earnings Per Share, Diluted -2.46 USD/shares 58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,721,393 USD 602%
Accounts Receivable, after Allowance for Credit Loss, Current $4,049,111 USD
Inventory, Net $22,639,342 USD 57%
Assets, Current $37,945,133 USD 107%
Property, Plant and Equipment, Net $275 USD -90%
Operating Lease, Right-of-Use Asset $835,177 USD 336%
Goodwill $9,346,796 USD 0%
Other Assets, Noncurrent $101,611,420 USD -0.56%
Assets $140,391,730 USD 16%
Accounts Payable, Current $11,021,412 USD 50%
Employee-related Liabilities, Current $3,094,395 USD 19%
Accrued Liabilities, Current $4,693,307 USD -25%
Liabilities, Current $38,207,120 USD -15%
Deferred Income Tax Liabilities, Net $8,035,000 USD 15%
Operating Lease, Liability, Noncurrent $681,640 USD
Liabilities $46,923,760 USD -9.4%
Retained Earnings (Accumulated Deficit) $247,024,914 USD -17%
Stockholders' Equity Attributable to Parent $79,958,162 USD 22%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $93,467,970 USD 36%
Liabilities and Equity $140,391,730 USD 16%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,008,822 USD -175%
Net Cash Provided by (Used in) Financing Activities $20,877,925 USD 711%
Common Stock, Shares Authorized 250,000,000 shares 1462%
Common Stock, Shares, Issued 22,376,427 shares 190%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,721,393 USD 602%
Interest Paid, Excluding Capitalized Interest, Operating Activities $14,460 USD
Deferred Tax Assets, Valuation Allowance $66,147,000 USD 23%
Operating Lease, Liability $829,646 USD 306%
Lessee, Operating Lease, Liability, to be Paid $987,187 USD 365%
Operating Lease, Liability, Current $148,006 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year Two $232,827 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $171,280 USD 698%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) $264,240 USD 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $157,541 USD 1971%
Lessee, Operating Lease, Liability, to be Paid, Year Three $237,686 USD
Deferred Tax Assets, Operating Loss Carryforwards $48,987,000 USD 23%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $242,545 USD
Additional Paid in Capital $326,960,700 USD 18%
Deferred Tax Assets, Net of Valuation Allowance $224,000 USD 234%
Share-based Payment Arrangement, Expense $10,836,291 USD 0%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%